This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schwartz, J. I. Articles by Gertz, B. J. Search for Related Content PubMed PubMed Citation Articles by Schwartz, J. I. Articles by Gertz, B. J.

MK-386, an Inhibitor of 5-Reductase Type 1, Reduces Dihydrotestosterone Concentrations in Serum and Sebum without Affecting Dihydrotestosterone Concentrations in Semen¹

Merck Research Laboratories (J.I.S., W.K.T., D.Z.W., D.L.E., L.A.G., A.D., B.J.G.), Rahway, New Jersey 07065; and Pharmaco:International, Inc. (B.H.), Austin, Texas 78704

Address all correspondence and requests for reprints to: Barry J. Gertz, M.D., Ph.D., Merck Research Laboratories, P.O. Box 2000, RY33–600, Rahway, New Jersey 07065-0900.

Two isozymes (types 1 and 2) of 5-reductase (5R; EC 1.3.99.5), with differential tissue distribution, catalyze the reduction of testosterone (T) to dihydrotestosterone (DHT) in humans. This study examined sequentially increasing oral doses of MK-386 (4,7ß-dimethyl-4-aza-5-cholestan-3-one), an azasteroid that specifically inhibits the human 5R1 isozyme in vitro. Finasteride, a selective inhibitor of 5R2, was included for comparison. One hundred men were evaluated in a double blind, randomized, placebo-controlled, sequential, increasing dose, parallel group trial. Ten to 20 subjects received MK-386, and 2 to 5 received placebo in each of 6 panels. In 1 panel, 10 subjects received finasteride (5 mg), and 5 received placebo. Treatments were given once daily for 14 days, except in 1 panel in which MK-386 was administered 10 mg twice daily for comparison to 20 mg daily. Serum, sebum, and semen DHT concentrations and serum and sebum T concentrations were measured before and after treatment.

The mean changes from baseline on day 14 for serum DHT after placebo and 0.1, 0.5, 5, 20, and 50 mg MK-386 were 6.9%, 4.6%, -2.7%, -1.2%, -14.1% (P < 0.05 vs. placebo), and -22.2% (P < 0.05 vs. placebo), respectively. No significant alterations in serum T were observed after any dose of MK-386. Serum DHT fell 65.8% from the baseline 14 days after finasteride treatment (P < 0.05 vs. placebo). The mean changes from baseline on day 14 in sebum DHT were 5.0%, 3.0%, -25.4% (P < 0.05 vs. placebo), -30.1% (P < 0.05 vs. placebo), and -49.1% (P < 0.05 vs. placebo) for the placebo and 0.5, 5, 20, and 50 mg MK-386 groups, respectively. Finasteride also reduced sebum DHT, but to a lesser extent (-14.9%; P < 0.05 vs. placebo). Reciprocal increases in sebum T concentration were noted at doses of 5 mg or more of MK-386, but not with finasteride. The mean reduction in semen DHT with 5 mg finasteride was approximately 88% (P < 0.01 vs. placebo); no significant change in semen DHT was noted with 20 or 50 mg MK-386. Serum 3-androstanediol glucuronide values were also reduced after the 20- and 50-mg MK-386 treatments in parallel with the changes in serum DHT. No meaningful changes were observed in serum LH after MK-386 treatment. MK-386 was generally well tolerated by all subjects; reversible aspartate aminotransferase/alanine aminotransferase elevations were observed in two subjects at the 50-mg dose.

The differential responses in serum, sebum, and semen DHT concentrations associated with MK-386 and finasteride treatments are consistent with those changes anticipated for selective inhibitors of the human 5R isozymes. Dose-dependent suppression of sebum DHT by a 5R1 inhibitor suggests the potential utility of such compounds in the treatment of acne.

This article has been cited by other articles:

				F. Sen, M. Demirturk, N. Abaci, E. Golcuk, H. Oflaz, A. Elitok, F. Kutluturk, H. Issever, N. E. Unaltuna, and N. C. Ozbey Endothelial nitric oxide synthase intron 4a/b polymorphism and early atherosclerotic changes in hypopituitary GH-deficient adult patients Eur. J. Endocrinol., May 1, 2008; 158(5): 615 - 622. [Abstract] [Full Text] [PDF]

				N. E. Allen, J. K. V. Reichardt, H. Nguyen, and T. J. Key Association between Two Polymorphisms in the SRD5A2 Gene and Serum Androgen Concentrations in British Men Cancer Epidemiol. Biomarkers Prev., June 1, 2003; 12(6): 578 - 581. [Abstract] [Full Text] [PDF]

				D. Thiboutot, E. Bayne, J. Thorne, K. Gilliland, J. Flanagan, Q. Shao, J. Light, and K. Helm Immunolocalization of 5{alpha}-Reductase Isozymes in Acne Lesions and Normal Skin Arch Dermatol, September 1, 2000; 136(9): 1125 - 1129. [Abstract] [Full Text] [PDF]

				V. A. Tobin and B. J. Canny The Regulation of Gonadotropin-Releasing Hormone-Induced Calcium Signals in Male Rat Gonadotrophs by Testosterone Is Mediated by Dihydrotestosterone Endocrinology, March 1, 1998; 139(3): 1038 - 1045. [Abstract] [Full Text] [PDF]